PGR and breast carcinoma: In this retrospective analysis, we sought to expand our previous observation that in patients with operable HER2-positive breast cancer, high co-expression of both the ER and PgR (“triple-positivity”-TP) could mitigate the effect of trastuzumab administered with adjuvant chemotherapy [13].